Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Liminal BioSciences Inc. LMNL

Healthcare Biotechnology

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed... see more

Add To Watchlist

Recent & Breaking News (NDAQ:LMNL)

Prometic to Report its Fourth Quarter and Year-end 2016 Financial Results and Hold Conference Call / Webcast

Canada NewsWire March 23, 2017

US FDA Grants Orphan Drug Designation to Prometic's PBI-4050 Drug for the Treatment of Alström Syndrome

Canada NewsWire March 3, 2017

ProMetic's PBI-4050 continues to demonstrate early evidence of efficacy following completion of idiopathic pulmonary fibrosis Phase 2 clinical trial

Canada NewsWire February 22, 2017

IIROC Trade Resumption - PLI

Canada NewsWire February 16, 2017

IIROC Trading Halt - PLI

Canada NewsWire February 16, 2017

IIROC Trade Resumption - ProMetic Life Sciences Inc.

Newsfile February 16, 2017

IIROC Trade Halt - ProMetic Life Sciences Inc.

Newsfile February 16, 2017

California Capital Equity, LLC acquires 44 million ProMetic shares through the exercise of all outstanding warrants

Canada NewsWire February 6, 2017

/R E P E A T -- ProMetic's PBI-4050 receives promising innovative medicine designation from the UK MHRA for the treatment of Alström Syndrome/

Canada NewsWire January 24, 2017

ProMetic's PBI-4050 Receives Promising Innovative Medicine Designation From the UK MHRA for the Treatment of Alström Syndrome

PR Newswire Europe Non Regulatory January 24, 2017

European Commission grants orphan drug designation to ProMetic's PBI-4050 drug for the treatment of Alström Syndrome

Canada NewsWire January 18, 2017

ProMetic reacquires plasminogen rights from Hematech

Canada NewsWire January 5, 2017

ProMetic initiates rolling submission of its Biologics License Application ("BLA") for plasminogen with U.S. FDA

Canada NewsWire December 19, 2016

ProMetic comments on unusual trading activity

Canada NewsWire December 16, 2016

ProMetic responds to false market data report regarding insider selling

Canada NewsWire December 9, 2016

ProMetic presents PBI-4050's positive effect on diabetic patients' kidneys at the American Society of Nephrology Annual Meeting

Canada NewsWire November 18, 2016

ProMetic's PBI-4050 Demonstrates Early Evidence of Efficacy in its Idiopathic Pulmonary Fibrosis ("IPF") Phase 2 Clinical Trial

Canada NewsWire November 17, 2016

ProMetic receives clearance from Health Canada to proceed with its PBI-4050 placebo-controlled phase 2 clinical trial in patients with metabolic syndrome and type 2 diabetes

Canada NewsWire November 16, 2016

ProMetic reports third quarter 2016 highlights and financial results

Canada NewsWire November 14, 2016

ProMetic's PBI-4050 shown to reduce pulmonary hypertension and lung remodeling and to improve right ventricular function in heart failure with reduced ejection fraction ("HFrEF")

PR Newswire November 14, 2016